Elucida Oncology CEO Geno Germano (L) and CFO and CBO Ian Somaiya
June 23, 2023 09:16 AM EDT
Financing
Startups

Elu­ci­da On­col­o­gy nabs more funds for its take on AD­Cs, sees po­ten­tial in ra­dio­ther­a­py part­ner­ship

Kyle LaHucik

Senior Reporter

Elu­ci­da On­col­o­gy has raised an­oth­er ap­prox­i­mate­ly $30 mil­lion to bring its ver­sion of an­ti­body-drug con­ju­gates to more pa­tients in the clin­i­cal set­ting, the com­pa­ny told …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times